Citations

Clear

71 citation(s) found for "Flick, M".

Longitudinal Surgical Modeling of Early Glioblastoma Recurrence Reveals Emergence of Margin-Associated Neural Programs
Malla, Adarsha P. , Flick, Matthew , Fang, Jennifer R. , Fan, Xiaoxuan , Chen, Chixiang , Beniwal, Angad , Sereduk, Chris , Drexler, Richard , Poulopoulos, Alexandros , Monje, Michelle , Anastasiadis, Pavlos , Tran, Nhan L. , Winkles, Jeffrey A.

Mayo Clinic

Cancer Research | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: OF1-OF20

10.1158/0008-5472.can-25-5176 | PMID 42831833 Get It

Abstract Glioblastoma (GBM) is a lethal, treatment-resistant brain cancer characterized by diffuse brain invasion, complex neuron–glioma signaling, and cellular, molecular, and spatial heterogeneity. Surgery is the current mainstay of treatment, aimed at maximizing tumor cytoreduction, decompressing the brain to improve neurologic function and providing material for analyses to inform prognostication and adjuvant treatment selection. To accurately model GBM surgical resection and tissue sampling in preclinical animal models, we developed the Maximal Safe Intracranial Surgery (MSIS) platform. MSIS integrated a miniaturized neurosurgical resection device and enabled a safe, tunable, and reproducible approach for intracranial tumor resection, multiregional biopsy, and longitudinal tissue sampling in murine models, with stereotactic, sterile, and high-viability tissue collection. MSIS was applied across five distinct orthotopic brain tumor models to reproducibly generate histologically and radiologically representative models of postsurgical GBM. Similar to humans, increasing the extent of resection correlated with improved animal survival, and recurrent growth patterns varied significantly by model type. Transcriptional profiles of matched primary versus postsurgical recurrent tumors revealed enrichment of margin-associated transcriptional states consistent with neuron–glioma signaling. Overall, the MSIS approach offers opportunities to model the standard of care, dissect the spatial and temporal dynamics of GBM, and pair therapeutic discovery with contextual tumor pathobiology. Significance: A clinically derived stereotactic resection platform models surgical resection in glioblastoma, enabling longitudinal tissue sampling and revealing conserved early-recurrence neuron-glioma programs in patient-derived models.
Anti-fibrinolytic strategies improve liver regeneration in mice and reduce post-hepatectomy liver failure in patients
Li, Zhihao , Wei, Zimu , Groeneveld, Dafna J. , Strilchuk, Amy W. , Flick, Matthew J., Dong, Yawen , Podrascanin, V. , Truty, Mark, Kendrick, Michael L., Cleary, S., Warner, Susanne G., Assinger, Alice, Kastrup, Christian J. , Karanicolas, Paul, Starlinger, P, Smoot, Rory L , Kastrup, Christian J , Luyendyk, James P , Li, Zhihao , Dong, Yawen , Flick, Matthew J. , Truty, Mark J. , Kendrick, Michael L. , Cleary, Sean P. , Warner, Susanne G. , Smoot, Rory L. , Assinger, Alice , Karanicolas, Paul J. , Luyendyk, James P.

Mayo Clinic

Blood Journal | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025029780 | PMID 42275251 Get It

Pharmacological plasminogen reduction enhanced liver regeneration experimentally and clinically. siRNA-induced plasminogen deficiency promoted hepatocyte proliferation after partial hepatectomy in mice, contrasting genetic deficiency models. In the HeLiX trial, tranexamic acid reduced post-hepatectomy liver failure odds, suggesting a novel therapeutic strategy.
OLIG2-STAT5 cooperation supports glioma stem cell maintenance and proliferation in glioblastoma
Miller, Aunay , McNamara, James, Blomquist, Mylan, Nascari, David, Flick, Matthew, Saladin, Sidney, Tuncali, Serdar, Sereduk, Christopher, Orndorf, Keely, Ensign, Shannon P Fortin, Loftus, Joseph C. , Mehta, Shwetal, Ensign, Shannon P. Fortin , Blomquist, Mylan R, Tran, Nhan L , Mehta, Shwetal , Ensign, Shannon P. Fortin , McNamara, James, Nascari, David , Tuncali, Serdar, Sereduk, Chris , Orndorff, Keely, Tran, Nhan L.

Mayo Clinic

Neuro-Oncology Advances | May 9, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag127 | PMID 42222434 Get It

Abstract Background Glioblastoma (GBM) is driven, in part, by glioma stem cells (GSCs), which sustain therapeutic resistance and recurrence. OLIG2 is a key regulator of GSC programs but the signaling pathways that cooperate with Oligodendrocyte transcription factor 2 (OLIG2) to maintain GSC states remain incompletely defined. Although Signal transducer and activator of transcription (STAT) signaling has been implicated in GSC biology, work to date has focused primarily on STAT3, and the contribution of STAT5 remains poorly defined. Here, we investigated whether STAT5B functionally cooperates with OLIG2 in sustaining GSC phenotypes. Methods Transcriptomic analyses, proximity ligation assays and biochemical studies were utilized to define OLIG2-STAT5B interactions in patient-derived GSCs. Functional consequences of OLIG2, STAT5B, BIRC5, and NUSAP1 suppression were assessed using small interfering RNA/short hairpin RNA-knockdown, stemness, and migration assays in EGFRvIII-expressing GSCs. In vivo tumor growth studies were performed using orthotopic xenograft models. Results OLIG2 and STAT5B expression were positively correlated in GBM datasets and patient-derived models. OLIG2 physically associated with STAT5B in EGFRvIII-expressing GSCs, and loss of OLIG2 reduced STAT5 activation, supporting a functional link between these factors. OLIG2 or STAT5B suppression induced convergent transcriptional changes, including downregulation of genes associated with GSC maintenance and proliferation, notably stemness regulators BIRC5 and NUSAP1. Silencing BIRC5 or NUSAP1 impaired GSC self-renewal and migration. In orthotopic models, STAT5B knockdown prolonged survival and phenocopied OLIG2 suppression and stemness loss. Conclusions These findings identify STAT5B as a functional partner of OLIG2 in GBM and define anOLIG2-STAT5B transcriptional axis that sustains GSC maintenance and malignant behavior. Targeting this axis may represent a therapeutic strategy to disrupt treatment-refractory glioma cell states.
The TNFR superfamily member Fn14 impacts immunity and survival in experimental gliomas and response to immune checkpoint inhibitor therapy in glioblastoma patients
Kanvinde, Pranjali , Seas, Alexandra A. , McFarland, Emylee, Fang, Jennifer R. , Flick, M, Connolly, Nina P, Beniwal, Angad , Sharifai, Nima , Chen, Chixiang, Anastasiadis, Pavlos , Winkles, Jeffrey A. , Woodworth, Graeme F, Chen, Chixiang , Kanvinde, Pranjali P , Sharifai, Nima , Chen, Chixiang , Bar, Eli E , Winkles, Jeffrey A , Woodworth, Graeme F , Malla, Adarsha P. , Connolly, Nina P. , Yepes, Manuel A , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology Advances | February 3, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag023 | PMID 41853810 Get It

Abstract Background Fibroblast growth factor-inducible 14 (Fn14) belongs to the TNFR superfamily. Fn14 overexpression can drive receptor-autonomous signaling, increase both cell invasion and tumor-associated macrophages/microglia (TAMMs) recruitment, and correlates with reduced survival in glioblastoma (GBM) patients and rat gliomas. While prior studies report Fn14 expression in non-tumor cells within the GBM tumor microenvironment (TME), their relative contributions to glioma pathobiology remain unclear. Methods Using tumor-host pairings of Fn14-positive and -knockout (-KO) cells and mice, we examined the role of Fn14 in glioma biology. Mouse glioma and human GBM datasets were analyzed at the cellular, protein, and transcriptomic levels to assess Fn14-associated changes in the glioma TME and survival outcomes. Results Fn14 was found to be highly expressed in tumor cells and TAMMs in human GBM and 2 well-characterized murine glioma models. Fn14 KO in both tumor and host cells increased overall survival. Notably, this survival benefit was greater in the glioma model characterized by a more immunologically activated TME. Immunophenotyping revealed that Fn14 loss reshapes the tumor-immune landscape, reducing the presence of immunosuppressive macrophages and exhausted T-cells, suggesting that Fn14 modulates both innate and adaptive immune responses. These findings were supported by analyses of human GBM datasets, where high Fn14 expression correlated with immunosuppressive shifts and poor patient responses to immune checkpoint inhibitor therapy. Conclusions This study provides the first description of the contributions of both tumor- and host-derived Fn14 expression to tumor immunity and survival and identifies Fn14 as an important mediator of innate and adaptive immune responses in gliomas.
Anesthesia and Babies’ Brains: Lessons from the Lounge
Flick, Randall P., Wilder, Robert T., Warner, David O. , Šprung, Juraj

Mayo Clinic

Anesthesiology | December 11, 2025 | Volume: 144 | Issue: 2 | Pages: 453-456

10.1097/aln.0000000000005808 | PMID 41379095 Get It

Early Exposure to Anesthesia and Learning Disabilities in a Population-based Birth Cohort. By Wilder RT, Flick RP, Sprung J, Katusic SK, Barbaresi WJ, Mickelson C, Gleich SJ, Schroeder DR, Weaver AL, and Warner DO. A nesthesiology 2009; 110:796–804. Reprinted with permission. Anesthetic drugs administered to immature animals may cause neurohistopathologic changes and alterations in behavior. The authors studied association between anesthetic exposure before age 4 yr and the development of reading, written language, and math learning disabilities. This was a population-based, retrospective birth cohort study. The educational and medical records of all children born to mothers residing in five townships of Olmsted County, Minnesota, from 1976 to 1982 and who remained in the community at 5 yr of age were reviewed to identify children with learning disabilities. Cox proportional hazards regression was used to calculate hazard ratios for anesthetic exposure as a predictor of learning disabilities, adjusting for gestational age at birth, sex, and birth weight. Of the 5,357 children in this cohort, 593 received general anesthesia before age 4 yr. Compared with those not receiving anesthesia (n = 4,764), a single exposure to anesthesia (n = 449) was not associated with an increased risk of learning disabilities (hazard ratio, 1.0; 95% CI, 0.79 to 1.27). However, children receiving two anesthetics (n = 100) or three or more anesthetics (n = 44) were at increased risk for learning disabilities (hazard ratio, 1.59; 95% CI, 1.06 to 2.37; and hazard ratio, 2.60; 95% CI, 1.60 to 4.24, respectively). The risk for learning disabilities increased with longer cumulative duration of anesthesia exposure (expressed as a continuous variable; P = 0.016). Exposure to anesthesia was a significant risk factor for the later development of learning disabilities in children receiving multiple but not single anesthetics. These data cannot reveal whether anesthesia itself may contribute to learning disabilities or whether the need for anesthesia is a marker for other unidentified factors that contribute to learning disabilities.
TMIC-78. Aquaporin-4 loss in astrocytes drives glioblastoma-associated cerebral edema and alters the tumor immune microenvironment
Flick, Matthew J. , Garvin, Kaisha, Vallcorba, Montserrat Puigdelloses, Ramos, Susana Isabel , Tsankova, Nadejda M. , Tran, Nhan L. , Hu, Leland , Heiland, Dieter Henrik , Tran, Nhan L , Joshi, Tanvi , Flick, Matthew J, Garvin, Kaisha, Dedhia, Mehek , Chen, Zhihong , Peters, Katherine B. , Smith, Alexander J. , Hambardzumyan, Dolores

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v462-v463

10.1093/neuonc/noaf201.1833 Get It

Abstract Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a dismal 5-year survival rate of ~6.5%. Vasogenic cerebral edema is a severe complication that occurs in the majority of GBM patients, leading to a significant increase in intracranial pressure, neurological deficits, and increased mortality rates. GBM-associated edema is almost exclusively managed by the corticosteroid dexamethasone, the use of which is associated with immunosuppression and interference with radiation therapy. While there is considerable research on edema formation, little is known about how edema resolution occurs in GBM, particularly in response to dexamethasone or other anti-edema therapies. This gap in understanding highlights the need for new approaches to treat edema effectively. The water channel aquaporin-4 (AQP4), a key player in the brain’s water homeostasis, is upregulated in GBM compared to the normal brain. To investigate the role of AQP4 in GBM-associated edema, we used the RCAS/tv-a system to generate de novo GBM with different driver mutations in Aqp4 knockout (KO) and wild-type (WT) mice. Our results indicated that Aqp4 KO tumor-bearing mice had shortened survival and increased edema content. Additionally, Aqp4 loss decreased astrocyte coverage specifically in the tumor core but not the tumor periphery. Our single cell RNA-seq data suggested that Aqp4 loss led to an astrocytic shift towards a less reactive, progenitor-like state, while also decreasing the myeloid and CD8+ T cell population in the tumor microenvironment. Interestingly, tumor-bearing mice treated with anti-VEGFA antibody, which has anti-edema properties, showed increased expression of Aqp4 and reduced vessel leakage. This suggests that AQP4 plays a critical role in mediating the effects of anti-VEGFA therapy. Overall, this study highlights the important role of AQP4 in the resolution of edema, while also revealing its additional effects on astrocyte activation and the immune microenvironment in GBM.
IMG-140. A network-based approach links novel patterns of multiparametric MRI to clinically relevant molecular signatures in high-grade glioma
Kenaston, Matthew W. , Flick, Matthew J. , Sereduk, Christopher, LaFond, Gabe, Langworthy, Jazlynn , Spahiu, Albana, Turkmani, Ali , Krishna, Chandan , Patra, Devi P. , Zimmerman, Richard S. , Swanson, Kristin R. , Tran, Nhan L. , Hu, Leland , Swanson, Kristin R , Tran, Nhan L , Flick, Matthew, Sereduk, Chris , Curtin, Lee , Baxter, Leslie C. , Bendok, Bernard R. , Kannan, Kasthuri S. , Ceccarelli, Michele

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v308-v308

10.1093/neuonc/noaf201.1218 Get It

Abstract High-grade gliomas (HGG) have significant spatial heterogeneity, complicating therapeutic approaches. While multiparametric MRI (mpMRI) enables noninvasive assessment of this heterogeneity, most predictive models lack biological interpretability when used to classify or predict outcomes. Here, we developed an unsupervised framework that identifies novel mpMRI feature patterns through dimensional reduction, linking them to clinically relevant molecular signatures. We analyzed 18 advanced mpMRI features from 73 stereotactic biopsies across 20 HGG patients. Imaging data were normalized, followed by dimensional reduction using an iterative UMAP across varying parameters. Density-based clustering was used to generate stable image-derived clusters through consensus co-clustering. RNA-seq data from matched biopsies were analyzed using DESeq2 and GSEA to identify differentially expressed genes and enriched pathways. We then constructed a network linking specific imaging features to these transcriptional signatures. Validation was performed in an independent cohort, allowing us to extend clusters across full brain mpMRI. Unsupervised clustering of mpMRI features produced nine stable image-based clusters. These clusters were not fully explained by contrast enhancement, metabolic class, or tumor purity, shown by intraclass correlation (ICC) analyses, suggesting they capture novel biological variation. Transcriptomic analysis showed each cluster was associated with distinct gene expression patterns and enriched biological pathways, including neuronal differentiation, immune chemotaxis, and chromatin remodeling. Key imaging features (sRCBV, MTT, K2)—combined in cluster-specific patterns—enabled construction of an interpretable imaging–transcriptomic network. This was validated in an independent cohort. We then applied to full brain mpMRI, mapping spatially distinct regions to biological trends and patient outcomes. Addressing a research gap in imaging HGG, we present an interpretable network that connects specific patterns of mpMRI to clinically meaningful molecular signatures. This approach advances our understanding of tumor heterogeneity and supports future translational work in precision patient care.
IMG-80. Non-Invasive Classification of Glioblastoma Subtypes at the Infiltrative Tumor Margin Using Multiparametric MRI and Graph Convolutional Networks
Flick, Matthew , Sarkar, Srijon , Sereduk, Christopher, LaFond, Gabe, Langworthy, Jazlynn , Zhou, Yuxiang, Spanhiu, Albana, Turkmani, Ali , Krishna, Chandan , Patra, Devi P. , Zimmerman, Richard S. , Swanson, Kristin R. , Tran, Nhan L. , Hu, Leland , Swanson, Kristin R , Tran, Nhan L , Sereduk, Chris , LaFond, Gabe, Curtin, Lee , Baxter, Leslie C. , Zhou, Yuxiang , Bendok, Bernard R. , Kannan, Kasthuri S.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v292-v292

10.1093/neuonc/noaf201.1159 Get It

Abstract BACKGROUND Glioblastoma (GBM) is a molecularly and phenotypically heterogeneous tumor, with regional invasion patterns driving treatment resistance and universal recurrence. In infiltrative regions, GBM cells adopt at least two predominant invasive phenotypes: Neuronal-enriched (NEU), with synaptic and neurodevelopment programs, and Glycolytic/Plurimetabolic (GPM), with heightened immune and metabolic activity. These subtypes differ in therapeutic vulnerability and microenvironmental interactions; features not captured by conventional contrast-enhanced (T1+C) MRI due to minimal blood-brain barrier (BBB) disruption. Our group sought to develop predictive models to distinguish variability of NEU/GPM subtypes within infiltrative GBM, utilizing graph convolutional networks (GCN), advanced multiparametric MRI (mpMRI), and spatially-matched image-localized biopsies with transcriptomic profiling. METHODS We analyzed 18 mpMRI features —including conventional, diffusion-weighted, and Dynamic Susceptibility Contrast (DSC) perfusion MRI— of 101 image-localized biopsies from MRI non-enhancing infiltrative margins of 64 GBM patient tumors. Features were hierarchically clustered per modality; each cluster was represented as a node in a Neo4j graph. Edges connected nodes sharing overlapping samples. Nodes were annotated with NEU or GPM subtype proportion. GCNs were trained to classify subtype-enriched nodes using graph topology and node features. RESULTS GCNs achieved high predictive performance on held-out test data (AUC = 0.95 for NEU, 0.88 for GPM; 70:30 train-test split) with similar 5-fold cross-validation performance and generalized well to an independent cohort (AUC > 0.85, n = 45). Importantly, performance was robust without relying on T1+C imaging, enabling prediction beyond BBB-disrupted regions. GCNs outperformed traditional classifiers (logistic regression, random forest). CONCLUSION Our results demonstrate that GCN-modeling of mpMRI features enables non-invasive prediction of invasive GBM subtypes at the tumor margin. Unlike convolutional neural networks (CNN), which rely on spatial continuity, GCNs leverage relational structure between heterogeneous imaging features, making them ideal for modeling sparse, non-grid data. This may support non-invasive regional vulnerability detection, surgical targeting, and improved response assessment.
STEM-19. OLIG2 AND STAT5 TRANSCRIPTIONAL AXIS DRIVES GLIOMA STEM CELL PROLIFERATION AND INVASION
McNamara, James, Miller, Aunay , Orndorff, Keely, Nascari, David , Blomquist, Mylan, Flick, Matthew J. , Sereduk, Christopher, Loftus, Joseph C. , Hu, Leland , Tran, Nhan L. , Mehta, Shwetal , Tran, Nhan L , Orndorff, Keely, Flick, Matthew, Sereduk, Chris

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v81-v82

10.1093/neuonc/noaf201.0327 Get It

Abstract Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) progression, therapy resistance, and recurrence, making them critical therapeutic targets. While the lineage-defining transcription factor OLIG2 is critical for GSC maintenance, the molecular co-regulators and downstream pathways it engages remain poorly defined. Here, we identify a previously unrecognized, functionally significant interaction between OLIG2 and STAT5B, uncovering a novel regulatory axis in GSCs. Using proximity ligation assay (PLA), we demonstrate that OLIG2 interacts with STAT5 in human and mouse GSC models, particularly in EGFRvIII-mutant cells. We find that OLIG2 preferentially partners with STAT5B and not STAT5A. Knockdown studies in GSCs reveal that OLIG2 and STAT5B co-regulate critical oncogenes BIRC5 and NUSAP1, both of which are required for sphere formation and migration capacity of EGFRvIII positive GSCs. In orthotopic xenograft models, knockdown of either STAT5B or OLIG2 significantly prolongs survival reduces expression of stemness and invasion markers, SOX2, VIMENTIN, and NUSAP1. In contrast, STAT5A knockdown fails to recapitulate these phenotypes, underscoring the role of OLIG2-STAT5B signaling in GSCs. These findings reveal a novel OLIG2-STAT5B transcriptional circuit that plays a role in GSC stemness maintenance, invasion, and tumor growth, particularly in EGFRvIII-driven gliomas. Targeting this axis may offer a new avenue for GBM treatment.
CSIG-26. SUBTYPE-SPECIFIC SIGNALING LANDSCAPES OF EGFR-G598V AND -A289V REVEAL TARGETABLE VULNERABILITIES IN INVASIVE GLIOBLASTOMA
Weaver, Sidney , Hansen, Nathaniel, Martinez, Melissa , Tuncali, Sedar, Flick, Matthew , Kloss, Jean , Sereduk, Christopher, Hu, Leland , Lavarone, Antonio, Pirrotte, Patrick , Loftus, Joseph C. , Tran, Nhan L. , Tran, Nhan L , Sharma, Ritin , D’Angelo, Fulvio , Tuncali, Sedar, Sereduk, Chris

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v89-v89

10.1093/neuonc/noaf201.0360 Get It

Abstract IDH-wildtype glioblastoma (GBM) is the most malignant primary adult brain tumor, with a five-year survival rate below 5%. Despite maximal treatment, including surgical resection, radiotherapy, and temozolomide (TMZ), recurrence is universal, driven by profound intratumoral heterogeneity, diffuse invasion, and therapy resistance. A hallmark of IDH-wildtype GBM is frequent alteration of epidermal growth factor receptor (EGFR), including amplification (50%), the EGFRvIII deletion variant (25%), and extracellular missense mutations such as G598V and A289V (10–15%). These missense mutations increase ligand affinity and receptor activity, yet their downstream signaling consequences and role in shaping the tumor phenotypes remain poorly defined. Recent pathway-based subclassifications identified four subtypes in IDH-wildtype GBM. Notably, neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes predominate the invasive tumor margins. NEU programs are enriched in synaptic and neurodifferentiation signals, while GPM programs are associated with metabolic adaptation, angiogenesis, and immune evasion. Here, we show EGFR-G598V and EGFR-A289V mutations differentially regulate these invasive subtypes identities. Transcriptional analysis reveals EGFR G598V upregulates metabolic and inflammatory pathways consistent with the GPM phenotype, while EGFR A289V activates genes involved in neuronal differentiation and synaptic function, aligning with the NEU subtype. Phosphoproteomics and kinase-substrate analysis further uncovered distinct kinases to be functionally activated/inhibited in EGFR A289V-expressing cells and G598V cells. Mechanistic studies revealed EGFR A289V induces sustained EGFR phosphorylation at Y992, activating PLCγ2 via the SRC-family kinase LCK. This cascade drives calcium release, CAMK1 activation, and STAT5 phosphorylation, defining a novel EGFR A289V–LCK/PLCγ2/CAMK1/STAT5 axis. In addition, Y1068 phosphorylation is also constitutively active in EGFR A289V, resulting in increased BRAF activation. In contrast, EGFR G598V activates MAPK6 and CAMK2 inducing AKT2 activation, reinforcing GPM-associated signaling. These findings uncover mutation-specific signaling networks that drive subtype fate in invasive GBM and highlight unique pathway(s) as tractable targets for subtype-directed therapy in EGFR-mutant GBM.